|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TXNDC15 |
Gene summary for TXNDC15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TXNDC15 | Gene ID | 79770 |
| Gene name | thioredoxin domain containing 15 | |
| Gene Alias | BUG | |
| Cytomap | 5q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q7Z345 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79770 | TXNDC15 | LZE4T | Human | Esophagus | ESCC | 1.88e-12 | 2.81e-01 | 0.0811 |
| 79770 | TXNDC15 | LZE7T | Human | Esophagus | ESCC | 3.97e-02 | 6.18e-02 | 0.0667 |
| 79770 | TXNDC15 | LZE8T | Human | Esophagus | ESCC | 7.84e-05 | 1.65e-01 | 0.067 |
| 79770 | TXNDC15 | LZE20T | Human | Esophagus | ESCC | 1.18e-02 | -2.09e-02 | 0.0662 |
| 79770 | TXNDC15 | LZE22T | Human | Esophagus | ESCC | 7.48e-04 | 2.37e-01 | 0.068 |
| 79770 | TXNDC15 | LZE24T | Human | Esophagus | ESCC | 1.13e-18 | 4.04e-01 | 0.0596 |
| 79770 | TXNDC15 | LZE21T | Human | Esophagus | ESCC | 4.69e-02 | 1.02e-01 | 0.0655 |
| 79770 | TXNDC15 | LZE6T | Human | Esophagus | ESCC | 1.70e-06 | 3.13e-01 | 0.0845 |
| 79770 | TXNDC15 | P1T-E | Human | Esophagus | ESCC | 8.11e-05 | 1.62e-01 | 0.0875 |
| 79770 | TXNDC15 | P2T-E | Human | Esophagus | ESCC | 1.08e-31 | 4.87e-01 | 0.1177 |
| 79770 | TXNDC15 | P4T-E | Human | Esophagus | ESCC | 2.39e-18 | 4.78e-01 | 0.1323 |
| 79770 | TXNDC15 | P5T-E | Human | Esophagus | ESCC | 7.21e-08 | 1.62e-01 | 0.1327 |
| 79770 | TXNDC15 | P8T-E | Human | Esophagus | ESCC | 1.47e-16 | 3.06e-01 | 0.0889 |
| 79770 | TXNDC15 | P9T-E | Human | Esophagus | ESCC | 5.83e-14 | 4.06e-01 | 0.1131 |
| 79770 | TXNDC15 | P10T-E | Human | Esophagus | ESCC | 3.93e-27 | 3.61e-01 | 0.116 |
| 79770 | TXNDC15 | P11T-E | Human | Esophagus | ESCC | 1.32e-10 | 6.36e-01 | 0.1426 |
| 79770 | TXNDC15 | P12T-E | Human | Esophagus | ESCC | 8.39e-31 | 6.18e-01 | 0.1122 |
| 79770 | TXNDC15 | P15T-E | Human | Esophagus | ESCC | 6.16e-19 | 5.14e-01 | 0.1149 |
| 79770 | TXNDC15 | P16T-E | Human | Esophagus | ESCC | 7.36e-23 | 3.36e-01 | 0.1153 |
| 79770 | TXNDC15 | P17T-E | Human | Esophagus | ESCC | 1.74e-07 | 3.31e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008589 | Thyroid | ATC | regulation of smoothened signaling pathway | 40/6293 | 81/18723 | 2.36e-03 | 1.10e-02 | 40 |
| GO:0007224 | Thyroid | ATC | smoothened signaling pathway | 60/6293 | 138/18723 | 9.75e-03 | 3.57e-02 | 60 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TXNDC15 | SNV | Missense_Mutation | novel | c.412N>T | p.Ala138Ser | p.A138S | Q96J42 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-HN-A2NL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| TXNDC15 | deletion | Frame_Shift_Del | novel | c.299delN | p.Ala101LeufsTer5 | p.A101Lfs*5 | Q96J42 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TXNDC15 | SNV | Missense_Mutation | novel | c.167N>T | p.Ala56Val | p.A56V | Q96J42 | protein_coding | tolerated(0.1) | benign(0) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| TXNDC15 | SNV | Missense_Mutation | rs773013478 | c.1042N>T | p.Arg348Trp | p.R348W | Q96J42 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TXNDC15 | SNV | Missense_Mutation | c.1028N>A | p.Arg343Gln | p.R343Q | Q96J42 | protein_coding | tolerated(0.09) | benign(0.328) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| TXNDC15 | SNV | Missense_Mutation | novel | c.752N>T | p.Ser251Ile | p.S251I | Q96J42 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| TXNDC15 | SNV | Missense_Mutation | c.1028G>A | p.Arg343Gln | p.R343Q | Q96J42 | protein_coding | tolerated(0.09) | benign(0.328) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| TXNDC15 | SNV | Missense_Mutation | novel | c.934N>T | p.Gly312Cys | p.G312C | Q96J42 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TXNDC15 | SNV | Missense_Mutation | rs773013478 | c.1042N>T | p.Arg348Trp | p.R348W | Q96J42 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TXNDC15 | SNV | Missense_Mutation | novel | c.704N>A | p.Arg235Gln | p.R235Q | Q96J42 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |